A detailed history of Royal Bank Of Canada transactions in Regenxbio Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,881 shares of RGNX stock, worth $39,389. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,881
Previous 4,604 6.02%
Holding current value
$39,389
Previous $53,000 3.77%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.49 - $14.39 $2,905 - $3,986
277 Added 6.02%
4,881 $51,000
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $26,783 - $50,100
2,327 Added 102.2%
4,604 $53,000
Q1 2024

Nov 05, 2024

SELL
$12.17 - $24.61 $28,319 - $57,267
-2,327 Reduced 50.54%
2,277 $47,000
Q1 2024

May 15, 2024

SELL
$12.17 - $24.61 $138,421 - $279,914
-11,374 Reduced 83.32%
2,277 $47,000
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $79,789 - $128,875
6,190 Added 82.96%
13,651 $245,000
Q3 2023

Nov 14, 2023

BUY
$16.46 - $19.99 $36,903 - $44,817
2,242 Added 42.96%
7,461 $122,000
Q2 2023

Aug 14, 2023

BUY
$17.23 - $21.71 $24,208 - $30,502
1,405 Added 36.84%
5,219 $104,000
Q1 2023

May 15, 2023

SELL
$18.08 - $24.55 $48,490 - $65,843
-2,682 Reduced 41.29%
3,814 $72,000
Q4 2022

Feb 14, 2023

BUY
$20.4 - $24.73 $104,019 - $126,098
5,099 Added 365.0%
6,496 $147,000
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $20,395 - $32,061
915 Added 189.83%
1,397 $37,000
Q2 2022

Aug 15, 2022

SELL
$19.35 - $35.04 $43,827 - $79,365
-2,265 Reduced 82.45%
482 $12,000
Q1 2022

May 16, 2022

SELL
$24.62 - $34.31 $126,866 - $176,799
-5,153 Reduced 65.23%
2,747 $91,000
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $119,552 - $159,508
3,960 Added 100.51%
7,900 $259,000
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $21,439 - $33,666
737 Added 23.01%
3,940 $165,000
Q2 2021

Aug 16, 2021

BUY
$32.46 - $40.48 $103,969 - $129,657
3,203 New
3,203 $125,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $349M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.